RedHill Biopharma Ltd.
RDHL
$1.64
-$0.09-5.20%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.55M | 8.80M | 8.04M | 5.88M | 3.71M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.55M | 8.80M | 8.04M | 5.88M | 3.71M |
| Cost of Revenue | 3.40M | 3.29M | 3.19M | 2.82M | 2.45M |
| Gross Profit | 6.16M | 5.50M | 4.85M | 3.06M | 1.26M |
| SG&A Expenses | 12.45M | 13.98M | 15.52M | 18.24M | 20.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -535.50K | -1.07M |
| Total Operating Expenses | 17.73M | 19.02M | 20.30M | 22.25M | 24.20M |
| Operating Income | -8.18M | -10.22M | -12.25M | -16.37M | -20.49M |
| Income Before Tax | -9.31M | -8.79M | -8.27M | -19.22M | -30.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -9.31 | -8.79 | -8.27 | -19.22 | -30.17 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.31M | -8.79M | -8.27M | -19.22M | -30.17M |
| EBIT | -8.18M | -10.22M | -12.25M | -16.37M | -20.49M |
| EBITDA | -7.91M | -9.82M | -11.73M | -15.69M | -19.51M |
| EPS Basic | -63.12K | -64.79K | -66.46K | -393.21K | -719.97K |
| Normalized Basic EPS | -2.80 | -2.91 | -3.01 | -22.82 | -42.63 |
| EPS Diluted | -63.12K | -64.79K | -66.46K | -393.21K | -719.97K |
| Normalized Diluted EPS | -2.80 | -2.91 | -3.01 | -22.82 | -42.63 |
| Average Basic Shares Outstanding | 6.18M | 5.56M | 4.93M | 4.03M | 3.13M |
| Average Diluted Shares Outstanding | 400.00 | 400.00 | 400.00 | 300.00 | 200.00 |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |